Search

Author/Creator Fishman, M.

3. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. Issue 1 (27th March 2019)

Authors:
Fishman, M.; Dutcher, J. P.; Clark, J. I.; Alva, A.; Miletello, G. P.; Curti, B.; Agarwal, Neeraj; Hauke, R.; Mahoney, K. M.; Moon, H.; Treisman, J.; Tykodi, S. S.; Daniels, G.; Morse, M. A.; Wong, M. K. K.; Kaufman, H.; Gregory, N.; McDermott, D. F.
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 7:Issue 1(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗